* KALYTERA THERAPEUTICS ENTERS INTO BINDING LETTER OF INTENT
TO ACQUIRE TALENT BIOTECHS AND ITS PHASE 2 CLINICAL-STAGE GRAFT
VERSUS HOST DISEASE PROGRAM
The post BRIEF-KALYTERA THERAPEUTICS ENTERS INTO BINDING LETTER OF INTENT TO ACQUIRE TALENT BIOTECHS appeared first on NASDAQ.